(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Breast Neoplasms · Invasive Breast Cancer · Estrogen-receptor-positive Breast Cancer · HER2-negative Breast Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 87 (planned)
- Started
- Feb 14, 2023
- Main results expected
- Nov 2026
- Fully finished
- Apr 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
PK Cohort - (Z)-endoxifen steady-state plasma concentrations
Measured over: After 4 weeks of treatment
For Analysis of Cohort A (Treatment Cohort): determine whether the week 4 Ki-67≤10% rate is at least 65%
Measured over: After 4 weeks of treatment
For analysis Cohort B (Treatment Cohort): determine the objective tumor response rate at 24 weeks
Measured over: After 24 weeks of treatment
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05607004 · record last updated 2026-07-08 · checked 2026-11-09 15:36 UTC